Researchers conducted the ACHIEVE-1 trial to assess the effect of orfoglipron on glycemic control among patients with early-stage type 2 diabetes.

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

YCT-529, a novel non-hormonal male contraceptive, demonstrates safety and tolerability in early trials, offering a potential ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

YourChoice Therapeutics, a biotech company based in California, has reported promising safety data from an early-stage ...